MyFinsight
Home
Blog
About
Income Statement
|
Cash Flow
|
Balance Sheet
|
Ratios
Income Overview
Net Income
-$24,150K
EPS
-$0.8
Unit: Thousand (K) dollars
Subscribe for Financial Insights
Page 1
Quarterly
123
Page 1
Income Statement
2026-06-30
2026-03-31
Research and development
20,336
19,461
General and administrative
5,743
4,151
Total operating expenses
26,079
23,612
Loss from operations
-26,079
-23,612
Interest income
2,858
1,219
Other (expense) income, net
-832
-282
Total other income, net
2,026
937
Loss before income tax expense
-24,053
-22,675
Income tax (expense) benefit
97
12
Net loss
-24,150
-22,687
Basic EPS
-0.8
-23.98
Diluted EPS
-0.8
-23.98
Basic Average Shares
30,111,338
946,000
Diluted Average Shares
30,111,338
946,000
Page 1
Unit: Thousand (K) dollars (except for numbers of shares and EPS). Numbers labeled with * are estimated quarterly values.
Page 1
Buy us a coffee
Time Plot
Show the time plot by selecting a row from the table.
Income Statement
Net loss
-$24,150K
Interest income
$2,858K
Loss before income
tax expense
-$24,053K
Income tax (expense)
benefit
$97K
Total other income,
net
$2,026K
Other (expense)
income, net
-$832K
Loss from operations
-$26,079K
Total operating
expenses
$26,079K
Research and development
$20,336K
General and
administrative
$5,743K
Buy us a coffee
Hemab Therapeutics Holdings, Inc. (COAG)
Hemab Therapeutics Holdings, Inc. (COAG)